Cargando…
Assessing the pathogenicity of BRCA1/2 variants of unknown significance: Relevance and challenges for breast cancer precision medicine
INTRODUCTION: Breast cancer (BC) is the leading cause of cancer-related death in women worldwide. Pathogenic variants in BRCA1 and BRCA2 genes account for approximately 50% of all hereditary BC, with 60-80% of patients characterized by Triple Negative Breast Cancer (TNBC) at an early stage phenotype...
Autores principales: | De Paolis, Elisa, Paris, Ida, Tilocca, Bruno, Roncada, Paola, Foca, Laura, Tiberi, Giordana, D’Angelo, Tatiana, Pavese, Francesco, Muratore, Margherita, Carbognin, Luisa, Garganese, Giorgia, Masetti, Riccardo, Di Leone, Alba, Fabi, Alessandra, Scambia, Giovanni, Urbani, Andrea, Generali, Daniele, Minucci, Angelo, Santonocito, Concetta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891372/ https://www.ncbi.nlm.nih.gov/pubmed/36741700 http://dx.doi.org/10.3389/fonc.2022.1053035 |
Ejemplares similares
-
BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making
por: Pavese, Francesco, et al.
Publicado: (2022) -
PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives
por: Fuso, Paola, et al.
Publicado: (2022) -
BRCA testing in a genomic diagnostics referral center during the COVID-19 pandemic
por: Minucci, Angelo, et al.
Publicado: (2020) -
BRCA testing delay during the COVID-19 pandemic: How to act?
por: Minucci, Angelo, et al.
Publicado: (2020) -
Tumor BRCA testing in ovarian cancer and EQA scheme: our experience of a critical evaluation
por: De Paolis, Elisa, et al.
Publicado: (2021)